Latest Discoveries

The newest verified discoveries, filterable by cancer type, evidence stage, advance type, intervention type, and biomarker — sorted by publish date, review date, or update date. Only Verified, non-suppressed stories appear here.

Filter latest discoveries

Results

132 verified discoveries match your filters.

Trial Watch: Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Lung Cancer
Published
August 27, 2026

ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study Comparing BL-M07D1 With Physician’s Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Colorectal Cancer
Published
August 27, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Prostate Cancer
Published
August 27, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Leukemia, Lymphoma
Published
August 26, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Leukemia, Lymphoma
Published
August 24, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Multiple Myeloma
Published
August 24, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Search all verified discoveries (text search, regulatory status, jurisdiction)